Exhibit 98

United States of America ex rel. Ven-a-Care of the Florida Keys, Inc. v. Boehringer Ingelheim Corp. et al.

Civil Action No. 07-10248-PBS

Exhibit to the August 28, 2009 Declaration of James J. Fauci In Opposition To Corrected Boehringer Ingelheim Corporation and Boehringer Ingelheim Pharmaceuticals, Inc.

Local Rule 56.1 Statement of Undisputed Material Facts
in Support of Their Motion For Summary Judgment

From: HEINS,JIM PA BIPUS Wednesday, March 01, 2000 9:19 AM Sent: To: WATERER, JUDY ROXUS

ROXUS PA BIPUS; SCHOBELOCK, KELLI Cc: DEMALA, PAM

FW: CCP_release Subject:

Importance: High

Judy,

Please see following comments from Shelly Berkle. Can you address Shelly's issues with Tom or would you like me to do it?

JWH

----Original Message-

PRESS,ROSEANN FN BIPUS On Behalf Of BERKLE, SHELLY **FN BIPUS** From:

Sent: Wednesday, March 01, 2000 9:15 AM

PA BIPUS To: HEINS,JIM

AD BIPUS; NURNBERGER, DAVID HR BIPUS Cc: GERSTENBERG,W

Subject: FW: CCP_release

Importance: Hiah

Jim,

No need to reference Tom's title and responsibility. Also, correct "NDA" to "ANDA" please. Additionally, I don't believe we will be at 'one ANDA/month' by 2001. Please check with Tom and do not release until I give the go ahead.

Shelly

---Original Message-

From: HEINS,JIM PA BIPUS Tuesday, February 29, 2000 2:54 PM Sent: To: BERKLE, SHELLY **FN BIPUS** PRESS, ROSEANN **FN BIPUS** Cc:

CCP release Subject:

Dear Shelly,

Attached for your review is a press release on the introduction of a new generic cytotoxic drug from Roxane. You'll see that Tom is quoted as

President and COO of Ben Venue Laboratories and Head of Multisource business at Roxane Laboratories, Inc.

In reading the release you'll see that Ben Venue is not mentioned in context. Also, Tom's responsibility for Roxane's multisource business is not well recognized in the industry or formalized in our corporate data sheets. While that may not be an issue, is there some way that you'd prefer to reference Tom's title and responsibilities in this and future promotional materials.

Please advisse.

Jim

w

CCP_release_.doc

F

ROX061-2338